Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
J Pediatr ; 166(4): 917-23, 2015 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-25661411

RESUMO

OBJECTIVES: To test the hypothesis that proton pump inhibitor (PPI) use results in changes in gastric microflora which, through full column reflux, results in lung and oropharyngeal microflora changes. STUDY DESIGN: We performed a prospective, cross-sectional cohort study of 116 children (57 off and 59 on PPIs) undergoing simultaneous bronchoscopy and upper endoscopy for the evaluation of chronic cough. We performed 16S sequencing on gastric, bronchoalveolar lavage, and oropharyngeal fluid. Fifty patients also underwent multichannel intraluminal impedance testing. RESULTS: Streptococcus was more abundant in the gastric fluid of patients taking PPIs, and there was a significant correlation with PPI dose (mg/kg/d) and abundance of gastric Streptococcus (P = .01). There was also a significant difference in the abundance of oropharyngeal Streptococcus in patients treated with PPI. Eight unique bacterial genera were found in the gastric and lung fluid but not in the oropharyngeal suggesting exchange between the 2 sites and 2 of the 8 (Lactococcus, Acinetobacter) were more abundant in patients with more full column reflux, suggesting direct aspiration. Principal component analysis revealed greater overlap between gastric and lung than oropharyngeal microflora. CONCLUSIONS: PPI use was associated with differences in gastric, lung, and oropharyngeal microflora. Although microflora exchange can occur between all 3 sites, gastric and lung microflora are more closely related, and the mechanism of exchange between sites may be aspiration of full column reflux.


Assuntos
Bactérias/efeitos dos fármacos , Refluxo Gastroesofágico/tratamento farmacológico , Pulmão/microbiologia , Orofaringe/microbiologia , Inibidores da Bomba de Prótons/farmacologia , Estômago/microbiologia , Adolescente , Bactérias/genética , Líquido da Lavagem Broncoalveolar/microbiologia , Broncoscopia , Criança , Pré-Escolar , Estudos Transversais , DNA Bacteriano/análise , Impedância Elétrica , Endoscopia Gastrointestinal , Monitoramento do pH Esofágico , Feminino , Seguimentos , Refluxo Gastroesofágico/fisiopatologia , Humanos , Lactente , Laringoscopia , Masculino , Estudos Prospectivos
2.
J Pediatr ; 165(1): 23-9, 2014 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-24529620

RESUMO

OBJECTIVES: To determine the impact of empiric ampicillin and gentamicin use in the first week of life on microbial colonization and diversity in preterm infants. STUDY DESIGN: The 16s ribosomal DNA community profiling was used to compare the microbiota of 74 infants born ≤32 weeks gestational age by degree of antibiotic use in the first week of life. The degree of antibiotic use was classified as 0 days, 1-4 days, and 5-7 days of antibiotic administration. All of the antibiotic use was empiric, defined as treatment based solely on clinical suspicion of infection without a positive culture result. RESULTS: Infants who received 5-7 days of empiric antimicrobial agents in the first week had increased relative abundance of Enterobacter (P = .016) and lower bacterial diversity in the second and third weeks of life. Infants receiving early antibiotics also experienced more cases of necrotizing enterocolitis, sepsis, or death than those not exposed to antibiotics. CONCLUSIONS: Early empiric antibiotics have sustained effects on the intestinal microbiota of preterm infants. Intestinal dysbiosis in this population has been found to be associated with elevated risk of necrotizing enterocolitis, sepsis, or death.


Assuntos
Antibacterianos/uso terapêutico , Enterobacter/efeitos dos fármacos , Recém-Nascido Prematuro , Intestinos/microbiologia , Microbiota/efeitos dos fármacos , Ampicilina/efeitos adversos , Ampicilina/uso terapêutico , Antibacterianos/efeitos adversos , Biodiversidade , Estudos de Coortes , Impressões Digitais de DNA , DNA Ribossômico/genética , Feminino , Gentamicinas/efeitos adversos , Gentamicinas/uso terapêutico , Idade Gestacional , Humanos , Recém-Nascido , Estudos Longitudinais , Masculino , Ohio , RNA Ribossômico 16S/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA